UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
ST. LOUIS, Aug. 03, 2017 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 second quarter ended June 30, 2017 on Thursday, August 10, 2017 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10:00 a.m. Eastern Time that day to discuss the Company’s results and corporate developments.
| What: | Stereotaxis second quarter 2017 financial results conference call |
| When: | Thursday, August 10th at 10:00 a.m. Eastern Time (7:00 a.m. PT) |
| Dial In Number: | To access the live call, dial 800-946-0706 (US and Canada) or 719-457-2642 (International) and give the participant pass code 1952158. |
| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at www.stereotaxis.com |
| Call Replay: | A phone replay of the call will be available for one week beginning approximately two hours following the end of the call through Thursday, August 17, 2017. To access the replay dial-in information, please click here. |
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.
Company Contacts: David L. Fischel Chairman and Acting Chief Executive Officer Martin C. Stammer Chief Financial Officer [email protected]
